Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: AZD2265 (FPI-2265)
DRUG: AZD9574
DRUG: Docetaxel
DRUG: AZD2287 (Imaging agent)

Sponsor

AstraZeneca